GLP-1 weight loss medications have evolved from ~15% weight loss with semaglutide (Wegovy 2.4 mg) to ~20%+ with higher-dose semaglutide (7.2 mg) and dual agonists like tirzepatide (Zepbound). Tirzepatide still shows slightly higher peak results, but high-dose Wegovy significantly narrows the gap, giving clinicians two viable paths to achieve near–bariatric-level weight loss. The Big Shift:
